Ra Pharmaceuticals (NASDAQ:RARX) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Thursday.

Several other research firms have also recently issued reports on RARX. BidaskClub upgraded Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, October 19th. Credit Suisse Group boosted their target price on Ra Pharmaceuticals from $14.00 to $17.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 7th. Raymond James upgraded Ra Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $28.00 target price on the stock in a research report on Wednesday, October 10th. Zacks Investment Research cut Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 10th. Finally, BMO Capital Markets set a $21.00 target price on Ra Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $20.80.

Shares of RARX stock opened at $11.97 on Thursday. Ra Pharmaceuticals has a 52-week low of $4.78 and a 52-week high of $19.43.

Ra Pharmaceuticals (NASDAQ:RARX) last issued its quarterly earnings results on Wednesday, November 7th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.02). As a group, equities research analysts predict that Ra Pharmaceuticals will post -2.14 EPS for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RARX. Cubist Systematic Strategies LLC increased its position in Ra Pharmaceuticals by 817.8% during the 1st quarter. Cubist Systematic Strategies LLC now owns 19,999 shares of the company’s stock worth $106,000 after purchasing an additional 17,820 shares during the period. Gabelli Funds LLC purchased a new stake in shares of Ra Pharmaceuticals during the 2nd quarter worth approximately $120,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Ra Pharmaceuticals during the 1st quarter worth approximately $128,000. Nisa Investment Advisors LLC purchased a new stake in shares of Ra Pharmaceuticals during the 2nd quarter worth approximately $157,000. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Ra Pharmaceuticals by 50.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 32,800 shares of the company’s stock worth $175,000 after acquiring an additional 11,000 shares in the last quarter. Institutional investors own 73.36% of the company’s stock.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Featured Article: Moving Average – How it Helps Investors in Stock Selection

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.